CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 225 enrolled
Drug / intervention
Restylane Contourdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05691972
NCT05691972N/ACompleted

A Randomized, No-treatment-controlled, Evaluator-blinded, Multi-center Study to Evaluate the Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing

Galderma R&D·interventional·Posted Jan 20, 2023·Updated May 22, 2026

In Brief

A clinical study evaluating Restylane Contour for Temporal Hollowing. Completed, enrolled 225 participants across 15 sites.

Detailed Summary

This is a randomized, no-treatment-controlled, evaluator-blinded, multi-center study to evaluate the effectiveness and safety of Restylane® Contour in correction of temple hollowing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJan 20, 2023
Enrollment StartMar 14, 2023
Primary CompletionOct 26, 2023
Study CompletionDec 11, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.4 years ago

Interventions

Restylane Contourdevice

a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)